actin-binding motif is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-12. Numbers and descriptions here follow the published literature rather than marketing material.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
Alkanes experiences intermolecular van der Waals forces. The cumulative effects of these intermolecular forces give rise to greater boiling points of alkanes. Two factors influence the strength of the van der Waals forces:
== Side effects == Adverse effects of vinblastine include hair loss, loss of white blood cells and blood platelets, gastrointestinal problems, high blood pressure, excessive sweating, depression, muscle cramps, vertigo and headaches. As a vesicant, vinblastine can cause extensive tissue damage and blistering if it escapes from the vein from improper administration.
=== May === 6 May – Michael D. Higgins and Leo Varadkar, respectively, became the first Irish president and taoiseach in history to attend the coronation of a British monarch, at Westminster Abbey in London. 9 May – The Irish band Wild Youth failed to qualify for the final of the Eurovision Song Contest. 11 May EirGrid announced plans for four major wind farm projects, three in the Irish Sea off the coasts of Counties Dublin and Wicklow and one off the Atlantic coast, in Connemara. The project is part of the largest ever renewable energy project in Ireland, intended to power six million homes by 2030. The High Court ruled that the diseased leg of an elderly man with dementia should not be amputated against his wishes in an attempt to save his life. 13 May – Taoiseach Leo Varadkar and Minister for Justice Simon Harris condemned scenes during a stand-off between pro-and anti-immigrant protesters in Dublin and a homeless asylum seekers' camp was destroyed by fire. 18 May Taoiseach Leo Varadkar expressed his dismay for a 14-year-old boy who was subjected to an unprovoked homophobic assault by a group of teenage boys in Navan and humiliated by having the video posted online. A 17-year-old boy who was attacked by a group of people using golf clubs in Bluebell, Dublin remained in a critical condition in hospital and in a coma. 20 May – Patrick Kielty was confirmed as the new host of RTÉ's The Late Late Show, taking over from Ryan Tubridy and becoming the show's fourth permanent presenter. 26 May The number of homeless people in Ireland exceeded 12,000 for the first time.
The grave was discovered by a farmer working in a potato-field at Hillside Farm on Bryher in March 1999, when his tractor wheel sank into the ground and to free it he moved a large stone which revealed the cist. He reached into the cavity and found a sword. He contacted the British Museum who advised him to take it to the Isles of Scilly Museum, where it was identified as a La Tène II iron sword. The then Prince Charles visited the farm while on a visit to the islands in May 1999, and a project for the evaluation, recording and reinstatement of the site was undertaken jointly by Cornwall Archaeology Unit, English Heritage and the British Museum.
Sources: en.wikipedia.org
Wild arapaima are harpooned or caught in large nets. Since the arapaima needs to surface to breathe air, traditional arapaima fishermen harpoon them and then club them to death. An individual fish can yield as much as 70 kg (150 lb) of meat. The arapaima was introduced for fishing in Thailand and Malaysia. Fishing in Thailand can be done in several lakes, where specimens over 150 kg (330 lb) are often landed and then released. On 14 May 2020, a 30 kg (66 lb) specimen was found floating in the river in Angkor Wat area, Krovanh village, Sangkat Norkor Thom, Siem Reap, Cambodia; the locals said it was a rare fish, and not commonly seen in this area. With catch-and-release after the fish is landed, it must be held for 5 minutes until it takes a breath. The fish has a large blood vessel running down its spine, so lifting the fish clear of the water for trophy shots can rupture this vessel, causing death.
In November 2022, Cerebras announced a partnership with Cirrascale Cloud Services to provide a flat-rate "pay-per-model" compute time for its Cerebras AI Model Studio. In November 2022, the National Energy Technology Laboratory (NETL) set milestones using Cerebras products. In November 2022, Argonne National Laboratory won the 2022 Gordon Bell Special Prize for COVID-19 research by using the CS-2 as well as products from Nvidia and Hewlett-Packard to transform large language models to analyze and predict variants of SARS-CoV-2. In July 2023, G42 agreed to pay around $100 million to purchase the first of potentially nine supercomputers from Cerebras. The first computer, Condor Galaxy 1 (CG-1), is capable of 4 quintillion floating-point operations per second (4 exaflops) of compute and contains 54 million cores. In November 2023, the second computer, the Condor Galaxy 2 (CG-2), was announced, with similar specifications as the CG-1. In March 2024, the companies broke ground on the Condor Galaxy 3 (CG-3), which can reach 8 exaFLOPs of performance and contains 58 million AI-optimized cores. In August 2023, Cerebras, the Mohamed bin Zayed University of Artificial Intelligence, and G42 subsidiary Inception launched Jais, a large language model. In March 2024, Cerebras introduced Wafer Scale Engine (WSE-3) architecture, a 5nm-based chip hosting 4 trillion transistors and 900,000 AI-optimized cores, and the basis for the CS-3. It has twice the performance of CS-2. The CS-3 was named to the list of the "best inventions of 2024" by Time.
guanine-cytosine content Also abbreviated GC-content. The proportion of nitrogenous bases in a nucleic acid that are either guanine (G) or cytosine (C), typically expressed as a percentage. DNA and RNA molecules with higher GC-content are generally more thermostable than those with lower GC-content due to molecular interactions that occur during base stacking.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.